October 15th, 2021
After a tough round of pitches and questions at the Valhalla Investors Summit BC, HTuO Biosciences is thrilled to advance on as one of the Top 11 Startups. The next round will see the top 5 companies advance, to be announced on October 21st, 2021.
September 24th, 2021
We are thrilled to announce that we have successfully closed the first tranche of our pre-seed round. With help from our co-lead investors VANTEC Entrepreneurs (VCC) Fund Inc., in Canada and SWAN Venture Fund, in the USA, we have received over $700,000 USD (out of $1M USD allotted for the round) from investors in Canada, the USA, and Europe. The funds will allow us to expand our team, in order to move our proof of concept to commercialization and ensure the continued operations of our business.
To all of our investors: Thank you for your contribution and support, with special thanks to those of you who have supported us since the beginning of our journey. Together, we will bring the most accurate molecular modelling to industry to address the most burning questions posed by pharmaceutical science.
August 20th, 2021
HTuO Biosciences is pleased to announce that Dr. Judith Herzfeld, Professor Emerita and Research Professor of Chemistry at Brandeis University, will become the first member of HTuO's Scientific Advisory Board on October 1st, 2021. Dr. Herzfeld brings a wealth of experience in molecular simulations and in the creative design of new force fields.
December 23rd, 2020
HTuO Biosciences has completed a Friends and Family Round of financing. For more information please contact firstname.lastname@example.org.
September 30th, 2020
HTuO Biosciences has officially incorporated in the province of British Columbia and begun operations. For more information please contact email@example.com.